
    
      This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging, parallel
      group study to evaluate the efficacy and safety of doxercalciferol given orally, once daily
      for 24 weeks to participants with moderate to severe chronic plaque psoriasis. Participants
      were randomized and stratified by site and Psoriasis Area Severity Index (PASI) score to one
      of three active treatment groups or to the placebo group.
    
  